TAIPEI, TAIWAN, July.7, 2022 - WASAI announced a partnership with Advantech, Intel, and Garaotus to advance rare disease and Parkinson’s disease genomics studies at MedGenome in India.
The partnership aims to bolster MedGenome, the market leader in genetic diagnostics in India, offering comprehensive genetic testing solutions that enable physicians and researchers to understand the diseases better. All the partners support MedGenome’s efforts to improve the at-scale genomics analysis workloads and provide a high-performance genomics analysis platform integrated with Advantech SKY-8232D, SKY-9232D, and SKY-5240 servers to boost the genomics analysis while improving TCO.
WASAI has been focusing on integrating the BWA+GATK pipeline, the Intel 3rd Gen Xeon and its FPGA acceleration card - Intel PAC D5005 to process 6 billion DNA base pairs with more cost-effective and scalable options. Our solution includes highly optimized algorithms for the complete set of acceleration tools to match the GATK Best Practice workflow. As one of 20 participating teams in PrecisionFDA Truth Challenge V2, our Bio-IT Platform showed high accuracy for genomics variant calling.
MedGenome has evaluated their Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), and standard benchmark samples with this accelerated architecture, which helps identify the performance of Intel’s different generation Xeon Processors with or without FPGA acceleration. Advantech offers significant efforts in designing the best balance of x86 server-class processing with maximum I/O and offload density in a compact, short-depth chassis. Garaotus helps with all the integration and enables seamless genetic analysis operations on all the servers.
In this latest published white paper, you can see the remarkable performance results evaluated by MedGenome. And how WASAI, Advantech, Intel and Garaotus offer these innovative new designs that deliver the performance and reduced TCO needed for the next generation of genomic analytics. Health and life sciences organizations are leveraging diverse patient data to drive more personalized care and improve outcomes. The result will facilitate more insights and treatments for a wide range of diseases and conditions and a better understanding of the human body.
Download the White Paper!
About WASAI Technology Inc.
WASAI Technology's mission is to deliver acceleration technologies of High-Performance Data Analysis (HPDA) in future data centers for targeted vertical applications with massive volumes and high velocities of scientific data. To strengthen and advance scientific discovery and technological research via big data-intensive acceleration in high-performance computing, WASAI Technology aims to improve commercialization and commoditization of scientific and technological applications.